中国驻利比里亚维和二级医院204例发热原因分析及处理

【目的】探讨中国第13批驻利比里亚维和医疗分队二级医院收治的发热患者的发热原因及处理方式。【方法】回顾性分析本院轮驻任务区期间发热患者的临床资料。【结果】在任务区8个月共收治发热患者204例，发热原因前三位为疟疾40．20％（82/204）、呼吸道疾病36．27％（74/204）、肠道感染10．29％（21/204），此外还有皮肤软组织感染、牙源性发热等疾病，通过口服抗疟药、抗感染药物、局部清创、对症处理等基本痊愈，少数血液病或不明原因发热患者转至三级医院治疗。【结论】在利比里亚维和任务区疟疾仍是造成发热的最主要原因，每例发热患者均要进行疟原虫检测。预防感冒及清洁饮食对减少呼吸道及肠道感染有重要意义。     

恶性疟凶险发作4例护理

疟疾分为4型，即间日疟、三日疟、卵型疟和恶性疟。其中恶性疟的病原为恶性疟原虫，恶性疟原虫的红细胞内期裂体增殖多在内脏微血管内进行，以内脏受损为主，特别是脑损害明显，从而导致寒战、高热和大汗，并且常伴有剧烈头痛、极度衰弱、全身肌肉酸痛和消化道症状，以及贫血和肝脾肿大等一系列临床表现。由于恶性疟原虫的大滋养体与裂殖体在内脏毛细血管内发育，并在感染原虫的红细胞膜上出现结节状突起，易发生粘连而使内脏毛细血管阻塞，所以有1％～2．5％的恶性疟患表现为中枢神经系统功能失常，呈现凶险发作。恶性疟凶险发作的患常有高热或超高热，体温升至40℃以上，并且持续不退，可出现嗜睡、神志不清、昏迷等神经系统症状，而且易发急性。肾功能衰竭、低血糖、肺水肿、心血管异常、黄疸及肝功能不全、血液系统异常和感染等并发症。刚果(金)是疟疾的高发区，其发病率居各种疾病的首位，其中95％为恶性疟。我国首支维和医疗分队刚果(金)执行维和任务的8个月时间内，收治患153例，其中疟疾患97例，占63％，疟疾患中90％以上为恶性疟。有4例恶性疟呈凶险发作，现将4例恶性疟呈凶险发作的患的护理介绍如下：     

蒿甲醚联合伯氨喹治疗恶性疟疾50例

目的:观察蒿甲醚联合伯氨喹治疗恶性疟疾的临床效果.方法:在利比里亚维和任务区采用随机分组将100例恶性疟疾患者分为联合组和对照组,对照组以口服蒿甲醚片为主,100 mg,每天1次,连用7 d,首剂加倍;联合组在此基础上加服伯氨喹片22.5 mg,每天1次,连用8 d治疗.所有病例治疗后14 d和28 d各随访1次.观察和记录病例的临床症状和药物的副作用.结果:对照组和联合组病例的临床治愈率为98.0%和100%,平均退热时间为(46.3±10.5)h和(44.6±11.7)h,平均原虫转阴时间为(34.7±11.2)h和(31.8±10.4)h,复燃率为34.0%和8.0%.结论:蒿甲醚片治疗恶性疟疾效果明显,副作用小.联合组复燃率明显低于对照组.     

阿立哌唑氯氮平喹硫平对康复期精神分裂症心肌酶和心电图的影响

目的 评价阿立哌唑、氯氮平及喹硫平对康复期精神分裂症患者心肌酶和心电图的影响.方法检测单一服用阿立哌唑(30例)、氯氮平(30例)、喹硫平(30例)治疗≥2 a的康复期精神分裂症患者的血清心肌酶及心电图,并进行对比分析.结果 3组间两两比较显示,(1)服药时间:阿立哌唑组服药时间显著小于氯氮平组和喹硫平组(P＜0.05),氯氮平组与喹硫平组差异无显著性(P＞0.05);(2)心肌酶变化:氯氮平组肌酸激酶同工酶显著高于阿立哌唑组与喹硫平组(P＜0.01),阿立哌唑组显著高于喹硫平组(P＜0.05);(3)心电图改变:3组心电图改变以窦性心动过速、T波改变最为常见,阿立哌唑组异常率13.3%、氯氮平组异常率86.7%、喹硫平组异常率为16.7%,氯氮平组异常发生率最高,3组差异有极显著性(H=9.5,P＜0.01).结论阿立哌唑、氯氮平及喹硫平对康复期精神分裂症患者的心肌酶和心电图均可产生一定的影响,但氯氮平影响更为显著,可能与氯氮平有极强的抗胆碱作用有关.     

北京地区境外输入性恶性疟疾临床分析——附99例报告

目的:探讨北京地区输入性恶性疟疾的临床特点及其诊断与治疗.方法:时99例输入性恶性疟疾患者的临床资料进行数理分析.结果:99例均有疟疾流行区居住史,临床表现复杂多样,其中发热99例(100%)、畏寒90例(90%)、头痛28例、呕吐25例、肌肉疼痛23例、腹泻21例、烦躁不安17例、贫血13例、肝肿大10例、脾肿大43例(43%)、双下肢水肿8例.21例早期误诊,误诊率为21%(21/99).43例给予氯喹治疗,其中16例经治疗无效,加用蒿甲醚治疗;41例应用双氢青蒿素加蒿甲醚治疗;15例应用蒿甲醚加双氢青蒿素哌喹治疗.99例全部治愈,治愈率为100%.3例出现再燃(3%).结论:恶性疟疾早期临床表现复杂,易误诊,临床上遇见有恶性疟疫区居住史的发热患者,应及时行血涂片或骨髓穿刺检查,以免延误诊治.使用青蒿素衍生物治疗恶性疟疾效果好,可作为首选药物.     

套式聚合酶链式反应在疟原虫检测和分型中的应用研究

目的比较疟疾病例样本套式PCR检测和传统镜检结果,探讨套式PCR在疟疾诊断中的应用价值。 方法采集疟疾患者血样,分别涂制厚、薄血膜用于常规镜检;抗凝血或滤纸血用于提取疟原虫DNA等。按要求设计属种等多套引物,应用套式PCR扩增感染人的4种疟原虫目的基因片段,将检测结果与镜检结果进行比较分析,并对目的片段进行测序鉴定等。 结果259份血样,套式PCR共检测出恶性疟187例、间日疟45例、卵形疟8例和三日疟1例,阴性10例。其中恶性疟阳性检出率最高(75.10%),间日疟阳性检出率次之(18.07%),还检测到混合感染血样8份(3.21%)。与GenBank标准序列对比显示,扩增片段大小及测序结果均完全正确,显示套式PCR在分型上比传统镜检更客观。套式PCR检测与传统镜检结果比较显示,前者阳性率(96.14%)明显高于后者(90.73%),并且差异具有统计学意义(χ²＝12.07,P<0.05)。 结论套式PCR法检测疟原虫具有较高敏感性和特异性,且适用于疟原虫混合感染,在疟疾病例诊断和分型方面均具有良好的应用前景。     

湖北省首例输入性卵形疟原虫wallikeri亚种的病原学诊断分析

目的应用巢式PCR技术对1例罕见卵形疟原虫wallikeri亚种进行诊断和鉴定。方法采集初诊为输入性间日疟患者血样,进行疟疾快速诊断试剂盒、显微镜镜检和巢式PCR检测,并进行测序分析。结果该患者疟疾快速诊断试剂盒检测阴性;镜检查见寄生于红细胞内的疟原虫环状体和滋养体;采用卵形疟原虫wallikeri亚种特异性引物(rOVA1v/rOVA2v)进行巢式PCR,在760bp处有特异性扩增条带,测序后经Blast比对,与GenBank数据库中卵形疟原虫wallikeri亚种部分序列的一致性为99%。结论该患者经巢式PCR和序列分析确诊为湖北省首例卵形疟原虫wallikeri亚种感染。     

5种抗精神病药物治疗精神分裂症对肝功能和心功能指标的影响

目的探讨阿立哌唑、氯氮平、奥氮平、利培酮、喹硫平5种抗精神病药物治疗精神分裂症对肝功能和心功能指标的影响。方法选取精神分裂症患者192例,按照随机表法分为5个组(氯氮平组38例、奥氮平组40例、利培酮组37例、喹硫平组35例和阿立哌唑组42例)。氯氮平组口服氯氮平片,奥氮平组口服奥氮平片,利培酮组口服利培酮片,喹硫平组口服喹硫平片,阿立哌唑组口服阿立哌唑片。各组疗程均为8周。比较各组疗效,观察治疗前后患者认知功能评定量表(LOTCA)评分、阳性和阴性症状量表(PANSS)评分、心功能指标、肝功能指标及副反应量表(TESS)评分的变化。结果各组总有效率比较,差异无统计学意义(P0.05);各组治疗后LOTCA评分较治疗前增加,而PANSS评分较治疗前降低(P0.05);各组治疗后LOTCA评分和PANSS评分比较,差异无统计学意义(P0.05);各组丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)及ALT+AST升高,各组差异无统计学意义(P0.05);各组治疗后左室射血分数和左室舒张末内径较治疗前降低(P0.05);各组治疗后左室射血分数和左室舒张末内径比较,差异无统计学意义(P0.05);利培酮组和喹硫平组TESS评分4周末和8周末均低于氯氮平组、奥氮平组、阿立哌唑组(P0.05);而利培酮组和喹硫平组TESS评分比较,差异无统计学意义(P0.05)。结论阿立哌唑、氯氮平、奥氮平、利培酮、喹硫平5种抗精神病药物治疗精神分裂症疗效明显,对肝功能和心功能影响小,且可改善患者认知能力和精神症状,其中利培酮和喹硫平不良反应较轻,具有重要应用价值。     

国产盐酸丙哌维林片治疗膀胱过度活动症的临床观察

42例膀胱过度活动症患者,均证实有尿频(24小时平均排尿次数等于或超过8次或夜尿等于或超过2次),尿急,有或不伴有急迫性尿失禁,平均每次排尿量少于200 mL,症状持续6个月以上。分成试验组22例和对照组20 例,采用双盲、双模拟随机方法服药。患者每日服药2次, 试验组予丙哌维林片20 mg加奥昔布宁模拟片5 mg,对照组予奥昔布宁片5 mg加丙哌维林模拟片20 mg,均以6周为1个疗程。     

哌氟喹酸可作治肾病综合征的首选药

已知原发性微小病变型肾病(MCN)和局灶节段性肾小球硬化(FSGS)。与T 淋巴细胞功能不全有关。传统的治疗药物有皮质类固醇和/或免疫抑制剂,如苯丁酸氮芥、硫唑嘌呤和环磷酰胺。但成人患者多易复发,完全缓解率MCN 约60%,FSGS20%,作者晚近以哌氟喹酸(Pefloxacin)治疗2例肾病综合征获得良效。现摘译1例如下:患者因MCN 肾病综合征第8次复发同意接受哌氟喹酸治疗。以往曾用皮质类固醇,环磷酰胺及硫唑嘌呤,但终未缓解。哌氟喹酸治疗的8天内24小时尿蛋白定量从15克降至0.15克、2周后停药,3月后     

Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand

The population pharmacokinetics of piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria treated with two different dosage regimens of dihydroartemisinin-piperaquine were characterized. Piperaquine pharmacokinetics in 98 Burmese and Karen patients aged 3 to 55 years were described by a two-compartment disposition model with first-order absorption and interindividual random variability on all parameters and were similar with the three- and four-dose regimens. Children had a lower body weight-normalized oral clearance than adults, resulting in longer terminal elimination half-lives and higher total exposure to piperaquine (area under the concentration-time curve from 0 to 63 days [AUC day 0-63]). However, children had lower plasma concentrations in the therapeutically relevant posttreatment prophylactic period (AUC day 3-20) because of smaller body weight-normalized central volumes of distribution and shorter distribution half-lives. Our data lend further support to a simplified once-daily treatment regimen to improve treatment adherence and efficacy and indicate that weight-adjusted piperaquine doses in children may need to be higher than in adults.     

A small amount of fat does not affect piperaquine exposure in patients with malaria

Dihydroartemisinin-piperaquine is a new, highly effective, and well-tolerated combination treatment for uncomplicated falciparum malaria. The lipophilic characteristic of piperaquine suggests that administration together with fat will increase the oral bioavailability of the drug, and this has been reported for healthy volunteers. This pharmacokinetic study monitored 30 adult patients with uncomplicated falciparum malaria for 4.5 months to evaluate the effects of the concomitant intake of fat on the total piperaquine exposure. The fixed-drug combination of dihydroartemisinin-piperaquine was given with water to fasting patients (n = 15) or was coadministered with 200 ml milk containing 6.4 g fat (n = 15). The drug combination was generally well tolerated, and there were no severe adverse effects reported for either group during the study. Total piperaquine exposure (area under the concentration-time curve from zero to infinity [AUC(0-∞)]; results are given as medians [ranges]) were not statistically different between fed (29.5 h · μg/ml [20.6 to 58.7 h · μg/ml]) and fasting (23.9 h · μg/ml [11.9 to 72.9 h · μg/ml]) patients, but the interindividual variation was reduced in the fed group. Overall, none of the pharmacokinetic parameters differed statistically between the groups. Total piperaquine exposure correlated well with the day 7 concentrations in the fasted group, but the fed group showed a poor correlation. In conclusion, the coadministration of 6.4 g fat did not have any significant effect on piperaquine pharmacokinetics in the treatment of uncomplicated malaria.     

Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites

The combination of piperaquine and dihydroartemisinin has recently become the official first-line therapy in several Southeast Asian countries. The pharmacokinetic mismatching of these drugs, whose plasma half-lives are ~20 days and ~1 h, respectively, implies that recrudescent or new infections emerging shortly after treatment cessation will encounter piperaquine as a monotherapy agent. This creates substantial selection pressure for the emergence of resistance. To elucidate potential resistance determinants, we subjected cloned Plasmodium falciparum Dd2 parasites to continuous piperaquine pressure in vitro (47 nM; ~2-fold higher than the Dd2 50% inhibitory concentration [IC(50)]). The phenotype of outgrowth parasites was assayed in two clones, revealing an IC(50) against piperaquine of 2.1 μM and 1.7 μM, over 100-fold greater than that of the parent. To identify the genetic determinant of resistance, we employed comparative whole-genome hybridization analysis. Compared to the Dd2 parent, this analysis found (in both resistant clones) a novel single-nucleotide polymorphism in P. falciparum crt (pfcrt), deamplification of an 82-kb region of chromosome 5 (that includes pfmdr1), and amplification of an adjacent 63-kb region of chromosome 5. Continued propagation without piperaquine selection pressure resulted in "revertant" piperaquine-sensitive parasites. These retained the pfcrt polymorphism and further deamplified the chromosome 5 segment that encompasses pfmdr1; however, these two independently generated revertants both lost the neighboring 63-kb amplification. These results suggest that a copy number variation event on chromosome 5 (825600 to 888300) is associated with piperaquine resistance. Transgene expression studies are underway with individual genes in this segment to evaluate their contribution to piperaquine resistance.     

Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria

Dihydroartemisinin-piperaquine is being increasingly used as a first-line artemisinin combination treatment for malaria. The aim of this study was to describe the pharmacokinetic and pharmacodynamic properties of piperaquine in 236 children with uncomplicated falciparum malaria in Burkina Faso. They received a standard body weight-based oral 3-day fixed-dose dihydroartemisinin-piperaquine regimen. Capillary plasma concentration-time profiles were characterized using nonlinear mixed-effects modeling. The population pharmacokinetics of piperaquine were described accurately by a two-transit-compartment absorption model and a three-compartment distribution model. Body weight was a significant covariate affecting clearance and volume parameters. The individually predicted day 7 capillary plasma concentration of piperaquine was an important predictor (P < 0.0001) of recurrent malaria infection after treatment. Young children (2-5 years of age) received a significantly higher body weight-normalized dose than older children (P = 0.025) but had significantly lower day 7 piperaquine concentrations (P = 0.024) and total piperaquine exposures (P = 0.021), suggesting that an increased dose regimen for young children should be evaluated.     

赤道几内亚Bioko岛的恶性疟原虫多药抗性基因（pfMDR—1）的研究

目的对赤道几内亚Bioko岛上恶性疟原虫多药抗性基因（pfMDR-1）进行分析,为Bioko岛的疟疾防控和治疗提供依据。方法2012年雨季期间采集的恶性疟原虫感染患者样本151份,用巢式PCR技术特异性扩增N86Y、E130K、Y184F、$1034C、N1042D、V1109I、D1246Y耐药分子标记的pfMDR-1基因片段．然后进行测序分析。结果虫株中共发现了4种不同的单倍型：YEY／SNVD、NEF／SNVD、YEF／SNVD和NEY／SNVD。91．39％（138／151）的样本发现了耐药性位点突变,包括3．31％（5／151）的86Y．29．80％的184F．和58．29％（88／151）的双重突变86Y／184F。结论结果表明赤道几内亚Bioko岛上的恶性疟原虫株存在较高比例耐药基因突变和耐药复合基因突变,为当地的抗疟疾选用药物提供指导。     

Randomized,Double-Blind,Placebo-Controlled Clinical Trial of a Two-Day Regimen of Dihydroartemisinin-Piperaquine for Malaria Prevention Halted for Concern over Prolonged Corrected QT Interval

Dihydroartemisinin-piperaquine, the current first-line drug for uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax in Cambodia, was previously shown to be of benefit as malaria chemoprophylaxis when administered as a monthly 3-day regimen. We sought to evaluate the protective efficacy of a compressed monthly 2-day treatment course in the Royal Cambodian Armed Forces. The safety and efficacy of a monthly 2-day dosing regimen of dihydroartemisinin-piperaquine were evaluated in a two-arm, randomized, double-blind, placebo-controlled cohort study with 2:1 treatment allocation. Healthy military volunteers in areas along the Thai-Cambodian border where there is a high risk of malaria were administered two consecutive daily doses of 180 mg dihydroartemisinin and 1,440 mg piperaquine within 30 min to 3 h of a meal once per month for a planned 4-month period with periodic electrocardiographic and pharmacokinetic assessment. The study was halted after only 6 weeks (69 of 231 projected volunteers enrolled) when four volunteers met a prespecified cardiac safety endpoint of QTcF (Fridericia''s formula for correct QT interval) prolongation of >500 ms. The pharmacodynamic effect on the surface electrocardiogram (ECG) peaked approximately 4 h after piperaquine dosing and lasted 4 to 8 h. Unblinded review by the data safety monitoring board revealed mean QTcF prolongation of 46 ms over placebo at the maximum concentration of drug in serum (C_max) on day 2. Given that dihydroartemisinin-piperaquine is one of the few remaining effective antimalarial agents in Cambodia, compressed 2-day treatment courses of dihydroartemisinin-piperaquine are best avoided until the clinical significance of these findings are more thoroughly evaluated. Because ECG monitoring is often unavailable in areas where malaria is endemic, repolarization risk could be mitigated by using conventional 3-day regimens, fasting, and avoidance of repeated dosing or coadministration with other QT-prolonging medications. (This study has been registered at ClinicalTrials.gov under registration no. {"type":"clinical-trial","attrs":{"text":"NCT01624337","term_id":"NCT01624337"}}NCT01624337.)     

N-乙酰半胱氨酸预防老年患者碘海醇造影致肾功能损害的研究

目的：探讨N-乙酰半胱氨酸（N—acetylcysteine,NAC）用于预防老年患者碘海醇造影致肾损害的临床应用价值。方法：将2011年9月至2012年10月我院静脉注射碘海醇行增强CT检查的老年患者74例根据患者检查顺序采用随机数字表分为治疗A组（A组,n=26）、治疗B组（B组,n=25）和对照组（C组,n=23）,A组患者于造影前48h和造影后48h口服NAC600mg,每日2次;B组患者于造影前48h和造影后48h口服NAC600mg,每日1次：C组患者于造影前48h和造影后48h口服安慰剂,每日1次。结果：本组共发生造影剂肾病（CAN）11例（14．9％）,A组CAN发生率显著低于B组和C组（P〈0．05）;A组造影后48h。肾功能指标明显优于B组和C组（P〈0．05）;造影后28h,5d和7d,A组24h尿蛋白明显低于B组和C组（P〈0．05）。结论：口服N-乙酰半胱氨酸600mg,每日2次可有效预防碘海醇造影所致老年患者肾功能损害。     

Randomized Comparison of the Efficacies and Tolerabilities of Three Artemisinin-Based Combination Treatments for Children with Acute Plasmodium falciparum Malaria in the Democratic Republic of the Congo

An open-label, randomized controlled trial was carried out in 2011–2012 in the Democratic Republic of the Congo to test the efficacy, safety, and tolerability of the artemisinin-based combination treatments dihydroartemisinin-piperaquine, amodiaquine-artesunate, and artemether-lumefantrine. Six hundred eighty-four children aged 3 to 59 months with uncomplicated Plasmodium falciparum malaria were randomly allocated to each study arm. Children were hospitalized for 3 days, given supervised treatment, and followed up weekly for 42 days. All regimens were well tolerated and rapidly effective. The median parasitemia clearance half-life was 2.2 h, and half-lives were similar between arms (P = 0.19). The PCR-uncorrected cure rates by day 42 were 73.0% for amodiaquine-artesunate, 70.2% for artemether-lumefantrine, and 86.3% for dihydroartemisinin-piperaquine (P = 0.001). Early treatment failure occurred in three patients (0.5%), one in each arm. The PCR-corrected cure rates were 93.4% for amodiaquine-artesunate, 92.7% for artemether-lumefantrine, and 94.3% for dihydroartemisinin-piperaquine (P = 0.78). The last provided a longer posttreatment prophylactic effect than did the other two treatments. The day 7 plasma concentration of piperaquine was below 30 ng/ml in 47% of the children treated with dihydroartemisinin-piperaquine, and the day 7 lumefantrine concentration was below 280 ng/ml in 37.0% of children who received artemether-lumefantrine. Thus, although cure rates were all satisfactory, they could be improved by increasing the dose. (This study has been registered with the International Standard Randomized Controlled Trial Number Register [www.isrctn.org] under registration no. ISRCTN20984426.)     

Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria

Intermittent preventive treatment (IPT) is increasingly used to reduce malaria morbidity and mortality in children and pregnant women. The efficacy of IPT depends on the pharmacokinetic and pharmacodynamic properties of the antimalarial drugs used. Healthy adult male volunteers whose occupation put them at high risk of malaria on the Northwest border of Thailand were randomized to receive a 3-day-treatment dose of dihydroartemisinin-piperaquine monthly (DPm) or every 2 months (DPalt) or an identical placebo with or without fat (6.4 g/dose) over a 9-month period. All volunteers were monitored weekly. One thousand adults were recruited. Dihydroartemisinin-piperaquine was well tolerated. There were 114 episodes of malaria (49 Plasmodium falciparum, 63 P. vivax, and 2 P. ovale). The protective efficacy against all malaria at 36 weeks was 98% (95% confidence interval [CI], 96% to 99%) in the DPm group and 86% (95% CI, 81% to 90%) in the DPalt group (for both, P < 0.0001 compared to the placebo group). As a result, the placebo group also had lower hematocrits during the study (P < 0.0001). Trough plasma piperaquine concentrations were the main determinant of efficacy; no malaria occurred in participants with a trough concentration above 31 ng/ml. Neither plasma piperaquine concentration nor efficacy was influenced by the coadministration of fat. DPm is safe to use and is effective in the prevention of malaria in adult males living in an area where P. vivax and multidrug-resistant P. falciparum malaria are endemic.     

苯磺酸氨氯地平和硝苯地平缓释片治疗原发性高血压的疗效观察

目的：比较苯磺酸氨氯地平和硝苯地平缓释片对轻、中度原发性高血压的降压疗效及安全性。方法：200例原发性高血压患者随机分成苯磺酸氨氯地平组和硝苯地平缓释片组,疗程8周,观察治疗前后血压变化,判断降压疗效并记录不良反应。结果：两组均能有效降低血压（P〈0.01）,苯磺酸氨氯地平组总有效率为95%,硝苯地平缓释片组总有效率为86%,两者比较差异无统计学意义（P〉0.05）。苯磺酸氨氯地平组不良反应（5%）显著低于硝苯地平缓释片组（14%）（P〈0.05）。结论：苯磺酸氨氯地平治疗轻、中度高血压具有较好的降压效果和依从性,不良反应轻微。